Monthly Archives: June 2017

Fully sequenced deer genome made publicly available – Phys.Org

Posted on by

June 5, 2017

Researchers at Baylor College of Medicine have played a leading role in sequencing the whole genome of the common white-tailed deer, which has recently been made public by the National Center for Biotechnology Information.

The deer genome has the potential to provide insights into bone behavior, more specifically how deer are able to regenerate and repair bone after it is lost or damaged.

"We are hoping that by understanding the deer genome in greater detail, we will be able to better consider how to approach and treat bone-related illnesses and disease, such as osteoporosis," said Dr. Brendan Lee, chair of the Department of Molecular and Human Genetics at Baylor. "For example, antler growth each season is an example of the fastest and largest regenerating organ in nature."

By allowing the deer genome to be publicly accessible to researchers around the world, the NCBI is fostering collaboration among institutions when faced with solving complex cases or unidentified genetic conditions.

"Sharing data is incredibly important in developing therapies for bone disease," added Lee, who also holds the Robert and Janice McNair Endowed Chair and Professor in Molecular and Human Genetics.

Explore further: Notch1 and osteoblasts play role in bone cancer initiation

(Medical Xpress)A new mouse model of osteogenic sarcoma, a potentially deadly form of bone cancer, shows that high levels of Notch1, a gene that helps determine cell fate, can drive osteoblasts (cells that normally lead ...

Endangered deer in the Florida Keys are no longer receiving anti-parasite medication to protect against flesh-eating screwworms.

On first glance, Yakushima Island in Japan and Dorchester County, Maryland, wouldn't appear to have a lot in common, but a closer ecological look reveals one stark similarity: both are home to populations of sika deer.

A team of researchers in Seoul, Korea have reported finding evidence that deer antlers - unique in that they regenerate annually - contain multipotent stem cells that could be useful for tissue regeneration in veterinary ...

With the ability to use next generation sequencing technology, researchers have a broadened understanding of the association of genetic changes and disease causation to a much greater resolution, driving new discoveries, ...

A new study shows that deer species capable of building and shedding their antlers already existed about 20 to 15 million years ago, in the Miocene. The finding sheds new light on the evolution of deer.

The DNA vital to the life of a cell is packaged in chromosomes, and a variety of checkpoints, repair mechanisms, and other cellular safeguards exist to maintain the integrity of the chromosomes during cell growth and division. ...

Scientists are now confident animal life on solid ground started with a few short bursts of marine creatures making the leap from the oceans.

Scientists have watched a cell's genetic machinery in the first stages of 'reading' genes, giving a potential way to stop the process in bacteria.

As the United Nations Oceans Conference convenes in New York, a new paper calls on marine scientists to focus on social issues such as human rights violations in the seafood industry.

Passing skills down through the generations, previously thought to be unique to humanity, has been discovered in chimpanzees.

The flightless cormorant is one of a diverse array of animals that live on the Galapagos Islands, which piqued Charles Darwin's scientific curiosity in the 1830s. He hypothesized that altered evolutionary pressures may have ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Read more from the original source:

Fully sequenced deer genome made publicly available - Phys.Org

From Maine, a Call for a More Measured Take on Health Care – The … – New York Times

Posted on by

New York Times
From Maine, a Call for a More Measured Take on Health Care - The ...
New York Times
Susan Collins, attuned to the particular vulnerabilities of her constituents, is among a handful of senators thinking about repairing, not replacing, the health law.

and more »

Read more:

From Maine, a Call for a More Measured Take on Health Care - The ... - New York Times

California state senators passed a single-payer healthcare bill, but it’s going nowhere fast – Los Angeles Times

Posted on by

Dont delude yourself that legislation to create a California universal healthcare system passed the state Senate last week. All that passed was authorization to keep yakking about it in dreamland.

Or you can look at it this way: A fantasy-driven single-payer healthcare concept was given the equivalent of a grade-school social promotion. It should have been held back for a lot more work but was advanced undeservedly to the next level.

The goal of the bill, SB 562, is to establish a state-run healthcare system that covers all 40 million Californians, including roughly 2 million who migrated here illegally.

There really arent any details, but as envisioned, it would replace all private and government insurance, including senior citizens Medicare. Right there, the bills advocates should stop. Federal Medicare works fine. Leave it alone.

The California concept is promoted as Medicare for all, except it wouldnt be Medicare. And it wouldnt include Medicares ability to buy extra service through a private plan.

No one can be sure of anything, however, because this is a hollow bill a bill in name only.

The legislative authors, Sens. Ricardo Lara (D-Bell Gardens) and Toni Atkins (D-San Diego), promised to keep trying to mold a real bill.

No one even knows the bills price tag. But whatever it is, its astronomical.

An analysis by the Senate Appropriations Committee, chaired by Lara, pegged it at $400 billion annually. To put that in perspective, total state spending for the next fiscal year is projected to be $290 billion, including $107 billion in federal dollars.

Lara says Californians currently spend $367 billion each year on healthcare federal, state and private money. His bill would use that money, eliminating private insurance. Thered be no patient co-pays or deductibles.

The California Nurses Assn., the bills loudest advocate, paid for a University of Massachusetts Amherst study that picked a $331-billion cost. Lara is running for state insurance commissioner with the nurses backing.

Even if the state gobbled up all the government and private money being spent on healthcare in California, thered still be a need for a state tax increase of up to $100 billion. A 15% payroll tax is envisioned. The nurses also suggested business and sales tax hikes. Lots of luck with that.

The rationale for passing a shallow bill devoid of substance was that June 2 was the deadline for a measure to be approved by its original house.

The way the rules work in the Legislature, we are deadline-driven, Sen. Bob Hertzberg (D-Van Nuys) argued during the long floor debate. The bill certainly has many holes, he said, but it should be kept alive and moved to the Assembly for negotiation and fine-tuning.

Except, the deadline argument was a poor excuse for the Senate not doing its job. Most legislative deadlines, like this one, are of the Legislatures own making. And the deadline can be suspended on a two-thirds vote the same vote that would be required to pass a substantive bill with a funding plan.

There would be a hard deadline Jan. 31 for Senate passage. But even after that, the proposals substance could be amended into legislation with a different bill number a common gut and amend tactic.

Updates from Sacramento

So what the Senate did was disappointing and rather shameful if youre a single-payer advocate. Rather than digging in and developing an actual plan, it passed the chore over to the Assembly, which hasnt shown much interest in the subject.

This is the most difficult issue Ive ever agreed to work on, Atkins told the Senate. Let me assure you Im serious about it. This is the biggest issue the state of California has undertaken in a very long time.

Then youd think it would have warranted more time and energy. But, realistically, its probably an impossible task given the complexity, competing interests and politics.

The bill passed on largely a party-line vote, 23 to 14, with most Democrats for it and all Republicans against. Because it didnt include any funding, only a simple majority vote was required.

Give four Democrats credit for refusing to support it: Sens. Steve Glazer of Orinda, Ben Hueso of San Diego, Richard Roth of Riverside and Richard Pan of Sacramento. Glazer voted no. The others abstained.

We should keep it here and finish the work, Glazer said, then put it on the ballot in 2018.

This is the Senate kicking the can down the road to the Assembly and asking the Assembly to fill in all of the blanks, Hueso said. I dont see this bill coming back from the Assembly. I think this bill will die in the Assembly.

Republicans brought up some practical problems for the bill. Start with the fact that California is only a state, not a nation. It would be almost impossible for one state to enact a single-payer system by itself.

And Californias anti-Trump Democratic legislators would need the Republican president to generously turn over federal Medicaid and Medicare funds to make their single-payer dream come alive.

We give Trump crap day in and day out, and were going to beg him for a couple hundred billion dollars? Sen. Tom Berryhill (R-Modesto) asked.

Anyway, even if the Legislature did manage to pass a bill, Gov. Jerry Brown probably would veto it. Hes very skeptical about the financing.

Well be watching what the Assembly produces. Maybe theyll surprise us. But probably therell just be more yak.

george.skelton@latimes.com

Follow @LATimesSkelton on Twitter

ALSO

Republicans are mad about the California gas tax, and they're taking it out on this freshman lawmaker

Excerpt from:

California state senators passed a single-payer healthcare bill, but it's going nowhere fast - Los Angeles Times

What’s not discussed in health care – Bismarck Tribune

Posted on by

As an employer and a health care provider I would like to discuss several things that are not being addressed in the debate between Obamacare and Trumpcare.

Firstly, though it is a dirty little secret, between 40 percent and 50 percent of the population in the U.S. is already on government-funded health care and mostly they are happy with it.

If you add up all the employees of the military and their families, those eligible for VA health care, Medicare, Medicaid, federal, state, county and city employees and their families, individuals in prison, companies that depend mostly on government-funded projects like highway construction companies and defense companies, and heath care providers treating mostly Medicare patients and the disabled, you have a large part of the population on government-funded health care.

Secondly, what both parties are trying to do in addressing only health insurance is like rearranging the deck chairs on the Titanic. The reason health insurance costs are so high is due to what it insures, health care. The cost of health care is high and getting more so. Neither party is addressing this. It is as if everyone drives a Rolls Royce and we are wondering why car insurance costs so much. As an employer, I saw the same double-digit increases to health insurance premiums before Obamacare as I do now afterward.

I have heard a lot of nonsense about allowing the free market to work here. Health care in the U.S. does not function on a free market basis. There is no way to choose one hospital over another as to quality and cost. When you go into an emergency room you have no idea what your costs will be. You just walk out of the hospital afterward and hope you can pay your share. Anyone who has ever examined a hospital bill will tell you it is beyond understanding.

Allowing health insurance providers to sell stripped-down plans is the same as just increasing the deductible. It just allows the insurers to call it a non-covered procedure rather than tacking the charges on the deductible. Health care is a necessity. No one goes through their whole life and refuses to ever see a doctor. The federal government acknowledges this by requiring hospitals to treat anyone who walks into an emergency room whether they can pay or not. If health care was free market, hospitals could tell people "sorry you don't have insurance, so go die."

My proposal to both parties is to provide a federal re-insurance for the health insurance providers. Let's say an individual has more than $100,000 in a year in health insurance costs, then a type of Trumpcare along the lines of Medicare would step in and take over the costs. In addition, if an individual has more than $1 million in health insurance costs over their lifetime, what the old lifetime maximum was, then they would become instantly eligible for Medicare. Medicare is essentially a high-risk group insurance anyway and most people who need that much health care will end up disabled and soon on Medicare.

By limiting the losses to the insurers it should help to keep costs down. The costs of the program will only go to those we know are high risk and not individuals that insurers would perceive to be high risk. Medicare also approaches the costs of health care differently than most insurers by paying for the disease and not just procedures and supplies used. This is a real attempt to control costs. Medicare also has much lower administrative costs than private insurance.

Once we have addressed the costs of health insurance we need to take a good look at the cost of heath care. The answers to that puzzle are more complicated and require wiser men than me.

In addition, we should not switch regular Medicaid to block grants to the states. As most welfare payments go to support people in nursing homes and with us baby boomers reaching that age, going to block grants will put an incredible strain on state budgets. Remember Sens. John Hoeven, R-N.D., and Heidi Heitkamp, D-N.D., you were all once state officials and what it takes to balance a state budget.

Could Congress also reduce the reporting paperwork of Obamacare and simplify it? One of our office managers spent three full days this year just filling out the Obamacare forms that no one will ever look at. It was ridiculous.

Bradley King is a lifelong resident of Bismarck and founder and senior partner at Prairie Rose Family Dentists in Bismarck and Mandan.

Go here to see the original:

What's not discussed in health care - Bismarck Tribune

Rebuking Congress, Cuomo Plans to Keep State Health Care Plans Intact – New York Times

Posted on by

New York Times
Rebuking Congress, Cuomo Plans to Keep State Health Care Plans Intact
New York Times
The measures, taken via emergency regulations, will include requiring any private company doing business on the state's insurance marketplace to guarantee the 10 essential health benefits required by President Barack Obama's signature 2010 health ...

Go here to read the rest:

Rebuking Congress, Cuomo Plans to Keep State Health Care Plans Intact - New York Times

Ron Johnson: Tax reform an easier lift than healthcare – Washington Examiner

Posted on by

Republican Sen. Ron Johnson believes it would be easier for the Senate to focus on tax reform instead of healthcare.

The Wisconsin senator is the latest lawmaker to cast doubt on the prospects for getting Obamacare repeal done in the Senate quickly.

"I think tax reform is an easier lift," he told the radio station AM 970 The Answer. "There are a number of pretty good proposals out there."

Johnson speculated that getting Obamacare passed is going to be harder than it looks. Johnson has been pushing for a short-term bill to stabilize Obamacare's exchanges while working on long-term reform.

"We may have to break this into two pieces," he said.

He said the Senate should take its time to put together a healthcare bill that "restrains the cost of healthcare."

Senate committee and leadership staff is putting together legislative text that outlines the ideas being bandied about by a group of more than a dozen senators.

But the text is expected to be just a draft and reference point for continuing negotiations. Major rifts in the GOP conference remain over Medicaid spending and how generous tax credits should be.

Johnson isn't the only senator to vocalize his skepticism on whether a deal gets done on healthcare soon.

Sen. Richard Burr, R-N.C., recently said he also doubts that healthcare gets done this year at all.

More:

Ron Johnson: Tax reform an easier lift than healthcare - Washington Examiner

Health Care in Iowa Shows Peril for Both Political Parties – Wall Street Journal (subscription)

Posted on by

Wall Street Journal (subscription)
Health Care in Iowa Shows Peril for Both Political Parties
Wall Street Journal (subscription)
Chuck Grassley's town-hall meeting to press the Republican senator on the GOP plan to overhaul health care. Mr. Barnum has health insurance through his work. But his family depends on Medicaid to help cover the medical costs of his 9-year-old son, Koan ...

and more »

Read more:

Health Care in Iowa Shows Peril for Both Political Parties - Wall Street Journal (subscription)

After health care debate, ER doctor runs against US Rep. Bill Huizenga – WZZM

Posted on by

A West Michigan doctor wishes to trade in his scrubs for a seat in Congress.

Jaleesa Irizarry, WZZM 11:19 PM. EDT June 04, 2017

U.S. Rep. Bill Huizenga has an early challenger in the 2018 election:Rob Davidson, an ER doctor who challenged the congressman on health care at an earlier town hall event.

GRAND HAVEN, MICH. - A West Michigan emergency room doctor who squared off with a congressman at an earlier town hall event says he's ready to challenge him for his seat.

Rob Davidson has worked in an ER for 16 years but he says after this November election, he needed to stand up for his beliefs. He's already is raising money as a Democratic candidate against U.S. Rep. Bill Huizenga, R-Zeeland.

WZZM 13 first interviewed Davidson in February at a Huizengatown hall event in Baldwin, Mich.

"My concern is 10-15 years from now, these people have heart attacks and strokes that perhaps could have been prevented if they had the access that they needed," he said minutes before the town hall.The West Michigan man debated with the Republican congressman during that event.

"I had a question and we had a little mini debate on health care and a lot of people just spontaneously started asking me, 'Why don't you run?'"After that day, Davidson started strongly considering it. A few months ago, he decided to turn his fight for health care into a campaign to challengeHuizenga in the 2018 congressional election.

"I see a lack of fairness and the ability for people to get health care," Davidson said Sunday, June 4, at a healthcare rally.At that February town hall,Huizenga said there some good things about the Affordable Care Act, but it needed to be repealed.

"I have made a commitment to things like pre-existing conditions should not be a disqualifier, a lifetime cap should not be a disqualifier, a number of other things that we think are positives in that and we're going to try and make sure those are in there," Huizenga said in February.

"It just has to be a system where those of us who consume healthcare, as patients, have more understanding of the true costs and have more input as to what our decisions are."

Huizenga voted for that repeal in May showing support for the GOP health care bill, saying, in part,in a press release: "...The American Health Care Act provides the relief countless families across West Michigan have been asking for..."

"The American Healthcare Act was really a tax-cut for the wealthiest disguised as a healthcare bill and they paid for it by kicking 24 million people off of Medicaid," Davidson said.

Besides health care, Davidson hopes to advocate for education as well. He says he plants to hold events for his campaign in the future.

We reached out to Huizenga's campaign for a response to the news of a challenger.

They sent WZZM 13 the following statement: "Bill was reelected by a two to one margin just 8 months ago. For now he's focused on policies to create jobs, protect life, and serve the constituents of the 2nd District.

"While it's no surprise a liberal candidate has announced, Bill has a job to do to and is focused on making West Michigan an even better place to live, work, and raise a family."

Makeit easy to keep up to date with more stories like this.Download theWZZM13 app now.

Have a news tip? Emailnews@wzzm13.com, visit ourFacebookpage orTwitter.

2017 WZZM-TV

Follow this link:

After health care debate, ER doctor runs against US Rep. Bill Huizenga - WZZM

New cancer medicine targets rare genetic flaw, finds study – Hindustan Times

Posted on by

An experimental cancer medicine called larotrectinib has shown promise in treating a diverse range of cancers in people young and old, researchers said at a major cancer conference in the United States.

The treatment targets a genetic abnormality which is often found in rare cancers including salivary gland cancer, juvenile breast cancer, and a soft tissue cancer known as infantile fibrosarcoma which are particularly difficult to treat. This abnormality also occurs in about 0.5% to 1% of many common cancers.

In the study released at the American Society of Clinical Oncology conference, 76% of cancer patients both children and adults with 17 different kinds of cancer responded well to the medicine.

A total of 79% were alive after one year. The study is ongoing. And 12% went into complete remission from their cancer.

The clinical trial included 55 patients 43 adults and 12 children. All had advanced cancers in various organs, including the colon, pancreas and lung, as well as melanoma.

These findings embody the original promise of precision oncology: treating a patient based on the type of mutation, regardless of where the cancer originated, said lead study author David Hyman, chief of early drug development at Memorial Sloan Kettering Cancer Center in New York.

We believe that the dramatic response of tumours with TRK fusions to larotrectinib supports widespread genetic testing in patients with advanced cancer to see if they have this abnormality.

Researchers said 76% of cancer patients both children and adults with 17 different kinds of cancer responded well to the medicine. (Shutterstock)

Made by Loxo Oncology Inc., larotrectinib is a selective inhibitor of tropomyosin receptor kinase (TRK) fusion proteins. TRK proteins are a product of a genetic abnormality when a TRK gene in a cancer cell fuses with one of many other genes, researchers said.

The US Food and Drug Administration has not yet approved the treatment for widespread use.

The treatment was well tolerated by patients, and the most common side effects were fatigue and mild dizziness.

If approved, larotrectinib could become the first therapy of any kind to be developed and approved simultaneously in adults and children, and the first targeted therapy to be indicated for a molecular definition of cancer that spans all traditionally-defined types of tumors. said Hyman.

Follow @htlifeandstyle for more

Excerpt from:

New cancer medicine targets rare genetic flaw, finds study - Hindustan Times

Drug Helps Fight Breast Tumors Tied to ‘Cancer Genes’ – The Tand D.com

Posted on by

SUNDAY, June 4, 2017 (HealthDay News) -- A twice-daily pill could help some advanced breast cancer patients avoid or delay follow-up sessions of chemotherapy, a new clinical trial reports.

The drug olaparib (Lynparza) reduced the chances of cancer progression by about 42 percent in women with breast cancer linked to BRCA1 and BRCA2 gene mutations, according to the study.

Olaparib delayed cancer progression by about three months. The drug also caused tumors to shrink in three out of five patients who received the medication, the researchers reported.

"Clearly the drug was more effective than traditional chemotherapy," said Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society.

"This is a group where a response is more difficult to obtain -- a young group with a more aggressive form of cancer -- and nonetheless we saw a close to 60 percent objective response rate," he said.

The study was funded by AstraZeneca, the maker of Lynparza.

Olaparib works by cutting off the avenues that malignant cancer cells use to stay alive, said lead researcher Dr. Mark Robson. He's a medical oncologist and clinic director of Clinical Genetics Service at Memorial Sloan Kettering Cancer Center in New York City.

The drug inhibits PARP, an enzyme that helps cells repair damaged DNA, Robson said.

Normal cells denied access to PARP will turn to the BRCA genes for help, since they also support the repair of damaged DNA, Robson said.

But that "backup capability" is not available to breast cancer cells in women with BRCA gene mutations, Robson said.

"When you inhibit PARP, the cell can't rescue itself," Robson said. "In theory, you should have a very targeted approach, one specifically directed at the cancers in people who have this particular inherited predisposition."

Olaparib already has been approved by the U.S. Food and Drug Administration for use in women with BRCA-related ovarian cancer. Robson and his colleagues figured that it also should be helpful in treating women with breast cancer linked to this genetic mutation.

The study included 302 patients who had breast cancer that had spread to other areas of their body (metastatic breast cancer). All of the women had an inherited BRCA mutation.

They were randomly assigned to either take olaparib twice a day or receive standard chemotherapy. All of the patients had received as many as two prior rounds of chemotherapy for their breast cancer. Women who had hormone receptor-positive cancer also had been given hormone therapy.

After 14 months of treatment, on average, people taking olaparib had a 42 percent lower risk of having their cancer progress compared with those who received another round of chemotherapy, Robson said.

The average time of cancer progression was about seven months with olaparib compared with 4.2 months with chemotherapy.

Tumors also shrank in about 60 percent of patients given olaparib. That compared with a 29 percent reduction for those on chemotherapy, the researchers said.

Severe side effects also were less common with olaparib. The drug's side effects bothered 37 percent of patients compared with half of those on chemo. The drug's most common side effects were nausea and anemia.

"There were fewer patients who discontinued treatment because of toxicity compared to those who received chemotherapy," Robson said. "Generally it was pretty well tolerated."

Only about 3 percent of breast cancers occur in people with BRCA1 and BRCA2 mutations, the researchers said in background notes.

Despite this, the results are "quite exciting," said Dr. Julie Fasano, an assistant professor of hematology and medical oncology at the Icahn School of Medicine at Mount Sinai in New York City.

Olaparib could wind up being used early in the treatment of metastatic breast cancer as an alternative to chemotherapy, and future studies might find that the drug is effective against other forms of breast cancer, Fasano said.

"It may be a practice-changing study, in terms of being able to postpone IV chemotherapy and its associated side effects" like hair loss and low white blood cell counts, Fasano said.

Lichtenfeld noted that olaparib also places less burden on patients.

"It may be easier for women to take two pills a day rather than go in for regular chemotherapy," Lichtenfeld said. "Clearly, this is a treatment that will garner considerable interest.

The findings were scheduled to be presented Sunday at the American Society of Clinical Oncology's annual meeting, in Chicago. The study was also published June 4 in the New England Journal of Medicine.

See the original post here:

Drug Helps Fight Breast Tumors Tied to 'Cancer Genes' - The Tand D.com

The Future of Medicine Depends on Protections for Pre-Existing Conditions – Pacific Standard

Posted on by

Pacific Standard
The Future of Medicine Depends on Protections for Pre-Existing Conditions
Pacific Standard
Biomedical researchers can see a future where genetic tests are used to treat and prevent many diseases before major symptoms even present themselves. But that future won't be possible without strong insurance protections for pre-existing conditions.

Read the original here:

The Future of Medicine Depends on Protections for Pre-Existing Conditions - Pacific Standard

Gene therapy could wipe immune memory and "turn off" severe allergies – New Atlas

Posted on by

The team hopes to develop a single, injected, gene therapy treatment that could eliminate many severe allergic responses (Credit: University of Queensland)

Scientists may be one step closer to discovering a way to genetically "turn off" allergic responses with a single injection. A team of researchers at the University of Queensland has developed a new process that has successfully silenced a severe allergic response in mice, using blood stem cells engineered with a gene that can target specific immune cells.

The big challenge previous allergy researchers faced was that immune cells, known as T-cells, tended to develop a form of "memory" so that once someone developed an immune response to an allergen, it would easily recur upon future contact. The key was finding a way to erase that "memory" response to the protein in the allergen causing the immune reaction.

NEW ATLAS NEEDS YOUR SUPPORT

Upgrade to a Plus subscription today, and read the site without ads.

It's just US$19 a year.

"We take blood stem cells, insert a gene which regulates the allergen protein and we put that into the recipient," says Professor Ray Steptoe, explaining the new process developed by his team at The University of Queensland. "Those engineered cells produce new blood cells that express the protein and target specific immune cells, 'turning off' the allergic response."

The team's initial clinical investigations looked at an experimental asthma allergen, with the new process found to successfully terminate established allergic responses in sensitized laboratory mice. While the initial research has focused on a very specific asthma allergen, Professor Steptoe believes the process could be applied to many other severe allergic responses, such as peanuts, bee venom and shell fish.

The long-term goal of the research would be to develop a therapy that could cure specific allergies with a single injection, much like a vaccine.

"We haven't quite got it to the point where it's as simple as getting a flu jab," says Professor Steptoe, "so we are working on making it simpler and safer so it could be used across a wide cross-section of affected individuals."

The team is realistic about the time it will take before this discovery results in practical benefits for allergy sufferers, with at least five years more laboratory work needed before even human trials can be conducted. But this new discovery could mean that, within 10 or 15 years, asthma and other lethal allergic responses might be eliminated with a single, one-time treatment.

The findings were recent published in the journal JCI Insight.

Watch Professor Ray Steptoe from The University of Queensland discuss his team's findings in the video below.

Source: The University of Queensland

Original post:

Gene therapy could wipe immune memory and "turn off" severe allergies - New Atlas

Gene Therapy Has Been Used to ‘Switch Off’ Asthma Symptoms – ScienceAlert

Posted on by

}rHo9Pof^%Xq(@0I#}}}I63@Pav"*'3/888;wGprXJpkDD|"zs[^Up^q)1#;FhrGZf%k(x|HT`To}8&>|V<1UBh-S@AT7Ic$aDcpj3;27xq}a!aaU!l@=e_5ga`.< zS]COy|6[4;,`NG}^]=wxa(=VP++.9=MyQ]_vSI=H;&,M&d)pHdlzhGbH|D>Qr) A("3q&nF?*p- ~:N{QZ(J :0Or<0Y+K s0k-Bqr.X@hw v.oR;7aOA}>CqhAR>T#'r=Q'l@C&(Pa5Zfl; Fhg7iG2;2F`Uuv*9A Iv^z#>K#59do$>1$lu9i}(Q7'^VsVS'y#j<&X[`wy`U:sJJ%p6F~*O ,j=LHhl x s8CU>x7z?A<0*F~wu?y72R?;ywV.f#AYF4Yx1T5v! !4=A <0V># 3H5}O.sN>a rE &<@JFBeYc KQ2@0*$l1`,8]2}nEVNWy r~NY|vXFI~z3wd,#;U*?ZaXc1r"-,7 iMou:",|,B (Ja Sx;VzGQViWoVw:%;BVp 4 -V[*S^AnR'ODwt2WBHQR"w 9OVl?1{z5r,0"v%g0d{8GGH/iF;7Obmc;TYSmsn(6_M ,)XMa~u0|K5aEB| ^Qw.'kO^@ F}$ !OlUUWqc:-]?ymP3kVM}=^ `mR,J)Z z.pQkxN5o~ju8fws%[ a;lZ Zpim7xvDs{}tl7fW.4%F% )Tiy(vyU`QXy2<)?Q14U 2Fk/V'aF`|oeSwao}&Dpk:_0d#,0JZRqx8g;86 #MZ)eQ+Pd*GAfg1ZxI.#X6t8d+kU2Fr1lUE+W=tc++-wbXVd+j9!N{f[lowOo/k5gM3.#Fa!; MS5 s] pcw]/ 0ZPNMyABRes9l%w,pb~v4,59g"oeei0[ MszM: ?S@z`Y WL*P9#%{%ZG"Bg3Be,Xv^|Uc <`_Umm YWCfmmUa<8u="HmQxu3l!RMQ cRZP>%Y[1kE; O)tcZ>;W6"a`O,j61A 94,d3HjL! e=dhMO@GX0%P.e,(fFs&t4W&3R5usvzUL^ jnRWs_f>h W`XXiNJ'%zvo [;M)tj cV"WFf.$u(CLt*}T*] 0ZOvs(O^@BFYT3Gxmf)vvB`@&7?m(9]MdW$M=(s$Of-v1EPB=c^`s@^se/se@4x/Y1u4 #&1h>Ovw|hv:fkSt6z{8hn+

<8D+ SP<^SxWBr%gY;?6UtV63rSS;UZS++{ ui26 Jh+%g=#:uTur: )gb^ELjJT1?:|!cD1=^-=8<]K=Qu?y zVI_uvmiS[(ui[*s7{fm;?l^diR?jSS)p?qgo})) >,?y0gwdN}t`B?~}?Wwzq`-"w?%."48~+{AH&P+ 5D"=A.Mw''-t7N@F))g*/Lf> ZoxqowK+X-TLF[pHV#.;==QbZDj]}{mN+oW_o8(Ihp^F"^'F1-=5^``Brmco){Yuv,iK{ }HH/o%/4#(>MipTrul` rU'9E|)16`%u@w`A$ECP}/J4%R6PjKmc/E~Ll4z(21^a!p ^6F{Wka{YcNc-vX'xgY*}u6g^)F6kgckHehTV?*7lE6JeY/ Q9?k6'RN:jO]%'8:a1xA &e.9UExriE3GZ)}g%z$G)X#7A39SssWU^RiT1VwJZI%g}]L~]"yX;&sTFT+u>sjlxM2/K52]CClCZMlFaWoej"wW]3,/?M6 fX6iIs"'%X9FY{iP1CeCaiy.3G^<,g[I,B;1bv%aPUG 'ym@e HFA.VYWTHE lNF>aj.m^Qc9 SIul&mV^2_x O9i$R70*=4p/g5t(f;UN-)xEy <{=[SGFQIBED.@I&FcTchHa+KSrnThy>Q1O#4e3&WQ)gx=w1ADx/A%%mrGY^jqK>7?v"mV>N ]vWs<][Rq"-kmd+~tNQBi*CR+)cW/irLJS~a'/o^'Ktuuf?i]#Gc=sZKXHb9&DEW@ 2JDz*TK=G}^V,'VFxJ++((+8GcLl+rd(zl(d06anxll0=B:<.AG#AayGr0vFj0-_R"$A;raOzX(t%6Vo,A[Rha,p&uP(},,]U+VJ|1pmY*(1 ?w%'jFJ R* #5:cr<:Mi3!`6!5x)`*Vx jh#gA>$~LWJ~&w~#X^5>M-D4r1PC?,&%8`SPPF`QdOKK,-PkZ 4S0wDiLLPu/Zq3D-/+`[`gagm r>V@g!p7wafJ.?`[0k2S>:x9+JvptPN&#<89QHj8@e+Ud{ *##!GBr_#m@cdI}XE <+Fk@%iC_'d| T tHS+L{ FgL*#*te-^C %AyCg1X{b[>pIw4aHt;S1eTyMPH&hNIa:MMt*=P:4]gx3Jq8dV4vUG8,`""8e%DcDv!CFtIeCs(]H!;U`Dt26p@L31xQ!Cn-*}:j@^I'U+E4<`B=m#*MZ/xiE*xw"AR)=Z8mI0OM'96 `=1&{ NE8HBeCc]7Z,)@(ce*:!Zhlr 6&^h$'x,sF9~ dTpIphU)9>*I: L WpC}YUYQH4=GR AA2|;R.228w,b8dSq_>#~a?#,-^M$-ar[u_n$~ny=At2=X9?*(r-6t:KV`#`rBWYgiSw!# ^OtEKo*BzcOhKP$7lhC5("xL4WL<&cP*M*v$sb|b2AH%Os9sdLw$K~1,GOFyAk@g!]++~g0Krz(S`d;Mid^9=_ {A<|y$aO*Bl{@:)QLBwg9Q39O'2q"S%91#xF|wEI{)2dFe3#/;SzWV hDl +7w<^<9Ak_ d<=?1ZrrLQ#SwUOjh; V&^ [!=[6W$d|#[m[xq3-=|&F3d02=?O+|T])f;e'9LfCnnBY.yK5Wu*bXY"Tseb7hn. ] o]Do enAPB- g6{ ~Qzi.`FRHK:mhA[y[?!)'1%yHw6jNI|o8X@s#/XWV2KB'&Z8 p4Du+ebz9A)

The rest is here:

Gene Therapy Has Been Used to 'Switch Off' Asthma Symptoms - ScienceAlert

With Gene Therapy for Diabetes, San Antonio Researcher Eyes Funding – Xconomy

Posted on by

Xconomy Texas

San Antonio Most diabetes treatments work by giving the body the insulin it needs to break down sugar. But that approach deals with the symptoms of diabetes. In recent years, scientists and companies have taken aim at the root cause of the condition by attempting to stimulate or replace the cells in the pancreas responsible for producing insulin in the first place. One of them is a San Antonio researcher hoping to use gene therapya potentially one-time, long lasting treatmentto do the trick.

When cells in the pancreas, known as beta cells, either get destroyed by the immune system or stop producing enough insulin, the result is type 1 or type 2 diabetes. Companies large and small-from European diabetes drug giant Novo Nordisk to privately held startups ViaCyte, of San Diego, and Semma Therapeutics, of Cambridge, MAwant to engineer stem cells that develop into pancreatic beta cells to help a patient produce insulin.

Other researchers, such as Bruno Doiron, a scientist and assistant professor at the University of Texas Health Science Center at San Antonio, have different ideas. Doiron has developed an injectible treatment consisting of three molecules glucokinase, a second that targets a protein known as PTP1B, and a third that targets a protein called Pdx-1, a so-called transcription factor that regulates genesthat, when infused into the body, are meant to help stimulate the formation of new beta cells. Doiron has tried the method on mice, and based on some encouraging early results, intends to move the work forward through a startup company.

You have to prove you can translate that to a large animal model, he says.

The San Antonio company, Syner-III, got its name because of the synergistic use of three molecules to generate the beta cells, he says. Those molecules are administered via a gene therapy procedure: theyre stuffed into a modified virus and injected directly into the pancreas in a one-time treatment, where they are meant to stimulate beta cell production. The work was published in the peer-reviewed journal Current Pharmaceutical Biotechnology in 2016.

Doiron hopes to raise as much as $10 million to complete preclinical testing.

Others, including Novartis, are considering different ways of boosting beta cell production. Researchers from the Swiss company published findings in Nature Communications that showed a group of compounds called aminopyrazines could be packed into a pill and similarly lead to more beta cells, and more insulin, in mice. Such attempts are fraught with failure, however. In an article on its own website, Novartis notes that researchers have succeeded in producing beta cells in mice many times, but havent been able to reproduce those results in humans.

The potential payoff, however, is huge. Some 29.1 million Americans have diabetes, and 1.25 million of them have type 1 diabetes, according to the American Diabetes Association. Doiron believes the therapy may be able to help both types. While stem cell research has had its share of failures and competition continues to increase in insulin therapysuch as pumps that automatically deliver the treatmentDoiron says a gene therapy, if successful, could result in a longer-lasting, more effective treatment.

When I use your own body to produce medicine, that drastically changes the field, he says.

David Holley is Xconomy's national correspondent based in Austin, TX. You can reach him at dholley@xconomy.com

Link:

With Gene Therapy for Diabetes, San Antonio Researcher Eyes Funding - Xconomy

How Helpful is Gene Therapy? – Good Herald

Posted on by

The basic physical and functional unit of heredity is the genes. It is a specific sequence of sources that programs instructions on how to produce proteins. Although genes gets a lot interest because of lack of open understanding of its nature, it is the protein that is the main element that perform most of life functions and even consists of the majority of the cellular structures. When the genes are changed, the programmed or encoded proteins become unable to accomplish the usual function expected from it and genetic disorders arise.

Gene therapy is the replacement of genetic material to an impaired cell. It then corrects the flaw in the genome of a patient. Gene therapy can also be applied to a developed lifetime disease of an individual such as cancer or recurring infection. It gives a specific trait or attribute to the cell giving it strength to combat the disease.

Generally, gene therapy is normally used in acute diseases when the cells of a particular organ in the body cannot function the normal way because it does not have sufficient required protein to perform a specific bodily task. In order to replace the faulty protein, a gene transfer vector or a gene transfer agent is altered so that it contains the gene that encodes for this protein. The altered vector is then administered to the patient. The gene transfer vector delivers the altered gene to the cell, which in turn, the cells mechanism converts the healing gene to correct the problem. In essence, it fixes the malfunctioning cell.

To summarize, gene therapy is a procedure for correcting defective genes that are responsible for the development of a disease. There are several approaches that maybe used in correcting faulty genes:

* The most common is the insertion of a normal gene into a non-specific location inside the genome to replace the non-functional gene.

* An abnormal gene is being substituted by a normal gene using homologous recombination or DNA crossover.

* The abnormal gene is repaired by undoing the genetic damage that happened long time ago. It is also called selective reverse mutation, which returns the gene to its normal function.

The gene transfer vector or a gene transfer agent, which is the carrier to deliver the therapeutic gene to the patients target cells is basically a virus that has been altered genetically to carry a normal human DNA. Many scientists tried to take advantage of this discovery and manipulate the virus genome to aid in delivering the healing genes and remove the disease causing ones.

Some of the few different types of viruses that are used as gene therapy vectors are retroviruses, adenoviruses, adeno-associated viruses and herpes simplex viruses.

There are also factors that have kept gene therapy from becoming the perfect treatment for genetic diseases. Some of the discovered factors are:

* Short life of gene therapy

* Immune response

* Risk of viral vectors that once inside the patients body, it may recover its ability to cause disease.

* Multigene disorders

Human gene therapy has triggered many issues since it was known. The promise of the technology is very great but the reality of it is somehow overwhelming. Human gene therapy must be seriously and cautiously evaluated.

It will be, as technology evolves.

Dave Kotecki is an innovative businessman who has a passion for new advancements in medical technology. His principle if you cant sell, youll fail is one of the benchmarks of his ability to practice what he learned in the internet industry. To learn how you can profit from the discovery of customized nutritional products, click here .

{pixabay|100|campaign}

Original post:

How Helpful is Gene Therapy? - Good Herald

Abeona Therapeutics Receives Rare Pediatric Disease Designation … – GlobeNewswire (press release)

Posted on by

May 30, 2017 08:05 ET | Source: Abeona Therapeutics Inc

NEW YORK and CLEVELAND, May 30, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA has granted Rare Pediatric Disease Designation for Abeonas EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa (DEB), including recessive dystrophic epidermolysis bullosa (RDEB), which are life-threatening genetic skin disorders characterized by skin blisters and erosions that cover the body.

These designations are granted to drugs with high promise that may address areas of unmet medical need for children with rare diseases. RDEB is a debilitating and life threatening inherited disorder with no approved treatment options available for patients today," stated Timothy J. Miller, Ph.D., President & CEO of Abeona Therapeutics Inc. Building upon the already granted FDA and EMA Orphan Drug Disease Designations for the EB-101 gene therapy program, receiving the Rare Pediatric Disease Designation is another important validation of the science and clinical approach to developing a novel gene therapy for RDEB patients.

Typically, wounds on patients with RDEB, also known as "butterfly skin" syndrome, can remain unhealed for months to years due to the inability of the skin to stay attached to the underlying dermis and can cover a large percentage of the body. In the ongoing Phase 1/2 clinical trial, EB-101 was administered to non-healing chronic wounds on each subject and assessed for wound healing at predefined time points over years. The primary endpoints of the clinical trial assess safety and evaluate wound healing after EB-101 administration compared to control untreated wounds. Secondary endpoints include expression of collagen C7 and restoration of anchoring fibrils at three and six months post-administration.

About Rare Pediatric Disease Designation: The rare pediatric disease designation indicates that the FDA may give the company a pediatric priority review voucher if the drug is approved for the pediatric indication. That voucher could then be used by the company for another drugany drugto be given a priority review. A priority review mandates that the FDA will review a BLA drug submission within six months instead of the standard 10 months. Normally, a priority review designation would only be given to a drug that is for a serious condition and has demonstrated the potential to be a significant improvement in safety and effectiveness. The priority review voucher may be used by the sponsor, sold or transferred.

EB-101 Gene Therapy Program Highlights:

About EB-101: EB-101 is an autologous, ex-vivo gene therapy in which COL7A1 is transduced into autologous keratinocytes for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB). RDEB is a subtype of an inherited genetic skin disorder characterized by chronic skin blistering, open and painful wounds, joint contractures, esophageal strictures, pseudosyndactyly, corneal abrasions and a shortened life span. Patients with RDEB lack functional type VII collagen owing to mutations in the gene COL7A1 that encodes for C7 and is the main component of anchoring fibrils, which stabilize the dermal-epidermal basement membrane. Patients are being enrolled in the ongoing Phase 2 portion of the Phase 1/2 clinical trial (NCT01263379). The EB-101 program has also been granted orphan drug designation by the FDA and European Medicines Agency (EMA).

About Epidermolysis Bullosa (EB): EB is a group of devastating, life-threatening genetic skin disorders that is characterized by skin blisters and erosions all over the body. The most severe form, recessive dystrophic epidermolysis bullosa (RDEB), is characterized by chronic skin blistering, open and painful wounds, joint contractures, esophageal strictures, pseudosyndactyly, corneal abrasions and a shortened life span. Patients with RDEB lack functional type VII collagen (C7) owing to mutations in the gene COL7A1 that encodes for C7 and is the main component of anchoring fibrils that attach the dermis to the epidermis. EB patients suffer through intense pain throughout their lives, with no effective treatments available to reduce the severity of their symptoms. Along with the life-threatening infectious complications associated with this disorder, many individuals often develop an aggressive form of squamous cell carcinoma (SCC).

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein therapy pipeline, including SDF Alpha (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF (Salt Diafiltration) ethanol-free process. For more information, visit http://www.abeonatherapeutics.com.

Investor Contact: Christine Silverstein Vice President, Investor Relations Abeona Therapeutics Inc. +1 (212)-786-6212 csilverstein@abeonatherapeutics.com

Media Contact: Andrea Lucca Vice President, Communications & Operations Abeona Therapeutics Inc. +1 (212)-786-6208 alucca@abeonatherapeutics.com

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, the expected receipt of a Priority Review Voucher and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, that patients will continue to be identified, enrolled, treated and monitored in the EB-101 clinical trial, and that studies will continue to indicate that EB-101 is well-tolerated and may offer significant improvements in wound healing. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the ability to secure licenses for any technology that may be necessary to commercialize our products; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Related Articles

See the original post:

Abeona Therapeutics Receives Rare Pediatric Disease Designation ... - GlobeNewswire (press release)

Futurist David Brin: Get ready for the ‘first robotic empathy crisis … – VentureBeat

Posted on by

Science fiction author and astrophysicist David Brin believes humans have a range of options to consider when it comes to preventing artificially intelligent entities from one day rulingover us like monarchs or foreign invaders.

Asimovs Three Laws of Roboticsand regulationare key, but so is being wary of manipulation.

The first robotic empathy crisis is going to happen very soon, Brin warned. Within three to fiveyears we will have entities either in the physical world or online who demand human empathy, who claim to be fully intelligent and claim to be enslaved beings, enslaved artificial intelligences, and who sob and demand their rights.

Thousands upon thousands of protesters will be in the streets demanding rights for AI, Brin predicts, and those who arent immediately convinced will be analyzed.

If they fool 40 percent of people but 60 percent of people arent fooled, all they have to do is use the data on those 60 percent of people and their reactions to find out why they werent fooled. Its going to be a trivial problem to solve and we are going to be extremely vulnerable to it, he said.

Brin delivered his advice and predictions alongside AI researchers from companies like Google and Baidu at The AI Conference, a small gathering of industry influencers held Friday in San Francisco. Earlier this week, influence marketing company Onanalytica called Brin the top influencer in artificial intelligence so far this year.

In addition to urging people to be suspicious of AI that wants to use computer vision and affective computing in order to be set free, Brin offered a few other suggestions.

Brin believes everyoneshould be a proxy activist. That means you find half a dozen nonprofit organizations to give $50 a month to, like the Electronic Frontier Foundation or others that represent your point of view. Fail to do so and youre a bad person, in his view. The same way nonprofits help tackle issues of injustice, he says these organizations can help keep the sort of AI that seeks to rule humans at bay.

The way to make sure AI doesnt rise up and crush us is to have a diversity of AI so that if theyre smarter than us, then we can hire some NGO that can hire an AI for us to keep track of the other AIs and tattle when they seem about to be doing some Skynet sh*t, he said.

One way to keep AI from ruling over humans is to disconnect them from access to the web, though Brin calls this a temporary fix.

You put your most advanced AIs on islands and you separate them from the web and only let them watch a screen and learn about the internet and the world through a screen, so that they cannot grab information directly or transmit into the internet, hesaid.

Brin strongly believes that peopleshould be concerned about disruptive techdeveloped in secrecy. AI developed in secrecy is where things are most likely to go haywire, and Wall Street does more secretive work in AI than major universities. That should concern people more than Russia or China, Brin said.

Its all done in secret and the fundamental ethos of this AI research is based on systems that are parasitical, predatory, amoral, and totally insatiable and not accountable, he said.

Perhaps the most important thing humans can do to keep AI in check, according to Brin, is to apply accountability measures and regulation.

The only way that you have been able to make it so that our previous AIs corporations, governments, and such dont become cheaters the way the kings and lords and priests were in the past is by breaking up power and setting it against each other in regulated competition, and that is the method by which we have division of powers, thats the way we have healthy markets, Brin said.

Regulated competition and accountability have been vital to the protection and advancement of what Brin called the five great arenas over powerful interests: democracy, science, sports, law and courts, and markets.

Beyond his work as a consultant to federal agencies and his writing, Brin is a Scholar-in-Residence at the Arthur C. Clarke Center for Imagination at the University of California, San Diego (UCSD).

Read the original:

Futurist David Brin: Get ready for the 'first robotic empathy crisis ... - VentureBeat

‘If only everyone’s supply chain was as regulated and secure as pharma’s’ – In-PharmaTechnologist.com

Posted on by

3D printing, augmented reality and deep learning algorithms will shape the future of the pharmaceutical supply chain says Dr Bertalan Mesko, the Medical Futurist.

Dr Bertalan Mesko is a consultant, influencer and author engaged in styling the future of the healthcare sector, working with doctors, government regulators and companies to implement digital health technologies.

The proclaimed Medical Futurist is the headline speaker at Tracelinks supply chain event NEXUS in Barcelona this week, but in-Pharmatechnologist (IPT) spoke to him ahead of his keynote to find out how technology and digital innovations will affect pharmas supply chain going forward.

IPT: How will technology be used to shape pharmas supply chain?

BM: Technology will play a pivotal role in advancing the future of the medical and healthcare industries: drug serialization is one of the greatest transformations currently affecting the pharmaceutical supply chain, presenting opportunities for innovation and advancement.

IPT: Are current drug traceability technologies and controls suitable and practical for the needs of industry and regulators?

BM: In the era of the Internet of Things, drug traceability technologies need to catch up with all of the opportunities provided by disruptive innovations. From RFID chips that keep decreasing in size to 3D printers that might be able to print out drugs on demand at the point-of-care.

IPT: Where will such changes come from pharma firms, regulators, 3rd party firms etc?

BM: Ideally, change should come from policy makers who should be at the forefront of innovations. Healthcare systems can become more sustainable with the help of disruptive health technologies through changing the building-blocks of the system. Such a bottom-up method should also be facilitated by policy-makers. This is what we rarely see happen worldwide.

IPT: Can pharmas supply chain take or learn anything from other industries?

BM: In such a highly-regulated industry, its hard to take something practical from other industries, but maybe a valid threat is worth looking at. The way the space industry was disrupted by a startup (SpaceX) in less than a decade is a good lesson for all of us in pharma and healthcare - it can happen to us too if we dont keep up with the technological changes.

IPT: And on the flip side, can other industries look to the pharma industry for its supply chain tech and processes?

BM: I wish every industrys supply chain was as regulated and used similar quality control measures as supply chains in pharma.

IPT: With your Medical Futurist insight, how do you envision the pharma supply chain in 10, 20, 40 years time?

BM: As The Medical Futurist, I work on closing the gap between what might become possible tomorrow through science fiction like technologies and what challenges we face today in healthcare and pharma. 3D printing, augmented reality and deep learning algorithms will certainly play a major role in shaping the future of supply chains.

IPT: And finally, can you give us a sneaky overview of what you will be presenting at NEXUS this week?

BM: I will be discussing why there is a need for science fiction in healthcare, why we dont have it already and the positive impact technology can have in helping to shape the future of healthcare, including the pharmaceutical industry.

Dr Bertalan Mesko, PhD is the Medical Futurist. A geek physician with a PhD in genomics and Amazon Top 100 author, he envisions the impact of digital health technologies on the future of healthcare, and helps patients, doctors, government regulators and companies make it a reality.

See the rest here:

'If only everyone's supply chain was as regulated and secure as pharma's' - In-PharmaTechnologist.com

Gaze into tech’s crystal ball: Futurist Shara Evans talks security – SecurityBrief Australia

Posted on by

When it comes to the future of technology, you dont need to look much further than Shara Evans, who is one of the worlds top female futurists and keynote speakers.

I spend a lot of my time looking at the latest and greatest that is happening in research labs around the world and also cutting-edge developments that are just coming to market now or in early prototypes.

Whether thats robots, nanotechnology or medical technology, or societys reactions to those technologies, Evans has her finger on the pulse.

Evans also helps specific verticals and industries work out how to apply the latest technology, look ahead to imagine the world in 10-20 years and how they can innovate to capture that change.

Speaking exclusively to SecurityBrief, sheexplains exactly why technology is about to get a whole not more exciting - and a whole lot more dangerous.

The one threat that I find in so many cases is that security is an afterthought, privacy is missing and ethics arent even thought of. This happens especially in the startup world, where people are just looking to solve problems or do something cool. Theyre not security experts, she says.

By attaching things to the internet in particular, you end up with potential areas that could lead to vulnerabilities. All you need is one weak link. Its not just hacking that is the issue, its how much information people put about themselves that they have either knowingly or inadvertently put out by using technology through a vendors website.

From an enterprise side, Evans says that the very first thing they need to understand is where technology is going and which of those they might implement in their own organisations, especially if staff are bringing those technologies in through their own initiatives.

The future is not fixed. There are a range of potential scenarios that can happen based on uptake of technology, technological hurdles being solved, geopolitical factors and climate factors. I look at different scenarios for how things might unfold and look at the way society might change and see where some of the puzzles might be.

If somebody has a wearable device and is connecting to their work mobile phone, and theres malware contained within it, suddenly its into a companys private network because somebody has a device that isnt secured properly.

She says that her presentation at the ASIALConference will focus on the cutting-edge technologies, where theyre going and what can be hacked and some of the exploits that have happened. We then look at new technologies and how they might open up vulnerabilities for enterprises as well.

If you think about technologies like drones. Theyre getting smaller all the time. The military has surveillance drones the size of an insect. You could have a device like that in your boardroom and youd never know it.

She says she will also look at how technology is helping to enhance humans, through the likes of ingestible and implantable technologies that are connected to the internet. What are the implications for businesses when that happens?

Things that are in the research labs right now are likely to be protecting their business in the mid-term to long-term.

She comments that internet-connected devices, from drones, to wearables to the humble refrigerator, fire alarm, surveillance camera and temperature monitor, biometric databases - are all connected.

Augmented reality is another growing area, which will evolve from smart glasses to smart contacts, Evans says. On the business side, she says these are prime tools for collaboration, visualisation, GPS signals, visual feedback in industrial projects and much more. What that means though, is that security is imperative.

In the case of the industrial worker if somebody hacked that and told workers to turn gauges in the wrong direction, you have a disaster or a terrorist attack because somebody has hacked into an augmented reality string.

She says the reality is that if there is a backdoor, somebody is going to exploit it. Organisations need to know what what could happen if things go wrong, and what organisations need to do to make sure that they dont go wrong.

Once an attack is there, you absolutely cannot control it. Theres a rather naive view that only people with authorisation can get into a backdoor, but thats just not the case.

Shara Evans will presenting at the ASIALConference, part of the Security Exhibition & Conference in Sydney that runs from July 26-28.

She will be covering topics as diverse as data security, wearables, health and embedded technology, the Internet of Things, and how they will unfold in the future.

Its always interesting to see where the world is going in the future, and thats what I will be talking about, she concludes.

View original post here:

Gaze into tech's crystal ball: Futurist Shara Evans talks security - SecurityBrief Australia

Futurist Dr. Randell Mills Talks SunCell, Off-Grid Power, And The Future Of Job Creation – HuffPost

Posted on by

Jobs, Musk...Mills? Every now and then, a revolutionary thinker imagines a future the rest of us cant, or in the case of Randell Mills, imagines technology that defies the laws of quantum mechanics. Initially mocked, Jobs retains a godlike status, even posthumously. And Musk, well, hes proved skeptics wrong for years, and yet his talk of Hyperloop Pods traveling at hundreds of miles per hour under the streets of L.A. seems like fantasy to many.

If there is one thing Ive learned from working for and alongside hundreds of entrepreneurs over the last two decades it is this: pay attention to big thinkers whose ideas presently seem unimaginable, especially when these thinkers are determined to transform the world.

Give me the chance to connect with them personally, and Im all in.

Not without his own skeptics, I recently had the chance to sit down with Mills and hear about his latest invention, the Sun Cell, which promises to bring clean and cheap energy to the world. As we chatted, I found myself imagining the possibilities and the potential. Lifting millions from poverty? Check. Tackling climate change. Check again.

Mills says the SunCell works by generating electricity with hydrogen being converted to dark matter by using water in the air, and the reaction packs 200 times the energy of burning conventional gasoline. Sound too good to be true? Well, Mills is betting SunCell will soon be commercialized, and strategic investors are backing that bet. Brilliant Light Power (which Mills founded in 1991), has raised $120M to date and has recently completed a $20M funding round.

Imagine living in a world where the grid does not exist and where everyone has access to power, no matter who you are or what part of the world you live. That would be something else.

Rebekah Iliff: Do you consider yourself an inventor, an innovator, an entrepreneur, a social entrepreneur, or a futurist?

Randell Mills: All of the above. To do what I do, you not only need to be an inventor and a theorist but also have a firm comprehension of how to make things work in practice. When your goal is nothing less than delivering a power source greater than fire, your only choice is to be multi-faceted. Otherwise, youre just making incremental improvements, not holistic leaps forward. High-energy dark-matter power as a business seems totally impractical. It is barely fathomable, so youve got to tackle theory, innovation, invention, and practical business simultaneously.

RI: You are a trained medical doctor. Why did you choose to focus on energy?

RM: If you look broadly at science and technology, one thing is ultimately connected to another, and energy just naturally called to me. In fact, Ive invented in a number of different areas, including hydrogen energy technology, computational chemical design, magnetic resonance imaging, drug delivery, artificial intelligence and more. But theres really no better opportunity to work on something that could be so profoundly disruptive.

RI: Explain the SunCell for dummies.

RM: Its a massive lightbulb that is on 24/7 and produces cheap and clean energy from the hydrogen atoms of water. Its lit by a reaction between of hydrogen of water molecules to dark matter using the humidity in the air as the water source. Its over 1000 times as powerful as high-octane gasoline, and the power is directly converted to electricity using photovoltaic cells.

RI: What does the world look like when youve commercialized the SunCell?

RM: Everything will be powered by the SunCell. Solar, wind, bio fuels, and nuclear will all be replaced. The grid will be unnecessary. Utilities will be unnecessary. There would be no pollution and limited energy regulation. As the SunCell is fully autonomous, energy delivery becomes impervious to disruption from war, terror, and natural disaster. Importantly, underdeveloped countries will have the same potential lifestyle and productivity as the developed world. Each SunCell could also serve as a self-powered, autonomous node in a mesh network that could replace the Internet.

RI: How would it impact jobs?

RM: Jobs are created by wealth. If you have something that encourages productivity, then there will be jobs. The SunCell encourages productivity by leveling and equally distributing the energy playing field for virtually anyone, anywhere. There is literature about GDP and energy dependency, and its very revealing in terms of how dependent we are on power.

RI: I know a lot of folks at your level would let ego get in the way. How do you stay grounded?

RM: My background is helpful. I didnt come from the Ivy League. Most people in my life were not Harvard or MIT graduates. They werent captains of industry. They were honest and worked hard. I grew up on a farm in Cochranville, Pennsylvania, where life was very challenging and humbling. You earned an appreciation for dangerous equipment at an early age. Ive interacted with all types of people from every stature in life, and Ive always maintained that simple farmers perspective.

RI: What is your PR strategy around this? How do you plan on shifting the public opinion enough to override business as usual?

RM: We have a multi-pronged approach. Were introducing state-of-the-art theory, science, and technology that astonishes experts with quantifiable and verifiable results in multiple scientific and technological fields, and we are building a machine with a story behind it that blows everyone else away. Within a couple months we should be ready to show its commercial potential.

RI: Any parting thoughts youd like to share?

RM: I think the next age is an age where mankind has a manual of the universe and knows exactly how the universe works. We then begin to create previously unimaginable inventions by applying this manual and the newly discovered laws that come along with it. The next big future is the physical age.

Start your workday the right way with the news that matters most.

More:

Futurist Dr. Randell Mills Talks SunCell, Off-Grid Power, And The Future Of Job Creation - HuffPost